Outcome | Unadjusted analysis | Adjusted analysis b |
|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
|---|
PFS-1TLc | 0.44 (0.27, 0.72) | < 0.01 | 0.60 (0.36, 0.98) | 0.04 |
OS-1TLc | 0.10 (0.02, 0.40) | < 0.01 | 0.14 (0.03, 0.59) | < 0.01 |
- CI Confidence interval; HR Hazard ratio; OS Overall survival; PFS Progression-free survival
- a Reference category is “not SHERBOC”
- b HRs are adjusted for age at study entry, tumor grade, Eastern Cooperative Oncology Group grading, metastasis pattern, and number of concomitant diseases
- c -1TL refers to the PFS or OS of the therapy line before a possible inclusion into the SHERBOC trial
